MedTrace Logo

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

NCT03208465 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-08-07

No results posted yet for this study

Summary

This trial evaluates the effects of Empagliflozin versus Sitagliptin, in addition to standard of care, on global myocardial perfusion reserve using dynamic single-photon emission computed tomography (SPECT) images.

Conditions

Interventions

DRUG

Empagliflozin

In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.

DRUG

Sitagliptin

In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.

Sponsors & Collaborators

  • CHEOL WHAN LEE, M.D., Ph.D

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-07
Primary Completion
2019-08-01
Completion
2019-08-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03208465 on ClinicalTrials.gov